ArticleMicrobiome research reports2025
Gut bioengineered models to study host-microbiota-probiotics interactions.
Article in Microbiome research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microbiome-guided cancer immunotherapy: immune mechanisms, resistance pathways, and translational opportunities for precision oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gastrointestinal tract is the major ecological niche in which gut microbes interact with epithelial and immune cells to maintain homeostasis in mammals. Moreover, probiotics modulate the gut microbiota and exert various health benefits after oral administration and persistence in the gut. Until now, animal models have been the gold standard for unravelling the mechanisms implicated in host-microbe interactions. However, their translational relevance to clinical trials and the associated ethical concerns underscore the need for alternative models. The emergence of microfluidic organ-on-chip technologies provides promising new alternative models to explore human host-microbe interactions while maintaining the tissue-level complexity and inter-individual variability. In this perspective, we discuss the potential of using mice, non-rodent models and gut-on-chip technologies to better characterize the interactions between the host, the gut microbiota, and orally administered probiotics, and to monitor microbial spatiotemporal dynamics at the tissue level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.